All News

2018

June

Media Release / Jun 27, 2018

Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month

Read More
Media Release / Jun 26, 2018

Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin

Read More
Media Release / Jun 18, 2018

Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery

Read More
Media Release / Jun 16, 2018

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

Read More
Media Release / Jun 15, 2018

Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

Read More
Media Release / Jun 15, 2018

Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer

Read More
Media Release / Jun 15, 2018

Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

Read More
Story / Jun 13, 2018

Women in Science: Kristen Harrington-Smith

Kristen Harrington-Smith discusses her work as Vice President and Head of CAR-T US at Novartis Oncology.

Read More
Media Release / Jun 13, 2018

Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis

Read More
Bernardo Bazet Lyonnet begins his search for a new medicine
Story / Jun 11, 2018

Open resources at Novartis help drive innovation

With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More